Lacking Cash, Targeted Genetics Unlikely to Move Huntington's Rx into Clinic in '09

Still, the company remains optimistic about therapeutic RNAi and continues target-identification efforts in preparation for when it raises the funds necessary to begin new programs incorporating the gene-silencing technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.